CARB-X is awarding $1.2 million to the Andrew G. Myers research group at Harvard University to develop enhanced antibiotics that target multidrug-resistant gram-negative bacterial pathogens, including Escherichia coli and Klebsiella pneumoniae, to treat urinary tract infections, pneumonia and bloodstream infections.
Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator (CARB-X) has awarded $1.1 million to Phiogen Inc. to evaluate PHI-BI-01, the company’s dual-action therapeutic designed to treat and prevent extraintestinal pathogenic Escherichia coli (ExPEC) bloodstream infections.
Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator (CARB-X) has awarded Baxiva AG $3 million to develop its multivalent glycoconjugate vaccine.
Centauri Therapeutics Ltd. and Kinvard Bio Inc. have separately announced new funding from CARB-X (Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator). The funds will support Centauri's ABX-01 program for multidrug-resistant bacterial strains and Kinvard Bio's oxepanoprolinamides program targeting lower respiratory tract infections as well as skin and soft tissue infections.
Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator (CARB-X) will award Arrepath Inc. $3.7 million to execute a lead optimization workplan for its first-in-class antibiotic targeting a clinically novel target for the treatment of complicated urinary tract infections caused by multidrug-resistant Enterobacterales.
CARB-X (Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator) has announced it will award US$2 million to Immunethep SA to develop a conjugated peptide-based vaccine to prevent infections from all invasive serotypes of Escherichia coli.
Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator (CARB-X) will award a seed grant of $610,000 to Justus Liebig University Giessen (JLU) to support the definition of a lead optimization path for the development of a direct-acting peptide therapeutic based on a natural-product scaffold targeting gram-negative pathogens.
Basilea Pharmaceutica Ltd. has been awarded an additional $7.3 million from CARB-X (Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator) to support the progression of the company’s novel antibiotic candidate, BAL-2420.
Vedanta Biosciences Inc. has been awarded $3.9 million in funding from the Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator (CARB-X) to advance its VE-707 preclinical development program for reducing colonization and preventing subsequent infections caused by multidrug-resistant organisms (MRDOs).
Basilea Pharmaceutica Ltd. has been awarded a grant from CARB-X (Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator) to support initial preclinical activities on the antibiotics program recently acquired from Spexis.
